What can be done about conflict of interest in pharmacy?

AUSTRALIA'S first comprehensive pharmacy review in two decades, released this week, asks the important question, “Is it confusing for patients if non-evidence based therapies are sold alongside prescription medicines?”

Let me save the reviewers some trouble: the answer is “yes”.

The harder question, of course, is “What, if anything, should be done about it at a regulatory level?” I don’t pretend to have an answer, but doing nothing at all will be a poor outcome for